FDA Warns Teva China Plant

Apr 13, 2017

Reuters

The U.S. Food and Drug Administration questions manufacturing controls at a Teva Pharmaceutical Industries plant in China, according to a Reuters article citing a regulatory filing on Thursday.

Teva received the FDA warning letter on April 10, with violations resulting from a regulatory inspection of its plant in September.

Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments